Topics:
Thoracic Malignancies • Medical Oncology
Would you consider first line therapy with PD-1 inhibitors (+/- CTLA4) for patients with metastatic NSCLC with high tumor mutational burden despite negative PD-L1?
How do you interpret the results of Checkmate 227 in light of Keynote 189 and Keynote 407?
Answer from: Medical Oncologist at Academic Institution
I would consider giving a patient with metastatic NSCLC and a high tumor mutational burden despite negative PD-L1 treatment with Nivolumab plus Ipilumumab. I would also consider giving the same patient chemotherapy plus a checkpoint inhibitor alone!The optimal treatment for this patient population ...
Sign in or Register to read more